The role of renin-angiotensin system modulation on treatment and prevention of liver diseases

Peptides

Volumn 62, Issue , 2014, Pages 189-196

  De Macêdo, Simone Moreira ^a   Guimarães, Talita Antunes ^a   Feltenberger, John David ^c   Santos, Sérgio Henrique Sousa ^a,b  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c TOURO UNIVERSITY NEVADA   (United States)

Author keywords

Angiotensin (1 7); Liver disease; Nonalcoholic fatty liver disease; RAS blockers; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT;

CELL ACTIVATION; CELL GROWTH; CELL PROLIFERATION; ENDOTHELIAL DYSFUNCTION; HUMAN; LIVER DISEASE; LIVER FIBROSIS; OXIDATIVE STRESS; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STELLATE CELL; GENETICS; LIVER DISEASES; METABOLISM; PATHOLOGY;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; LIVER DISEASES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 84910023050     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.10.005     Document Type: Review

References (95)

1. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-8.
2. Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol 2008;93:528-37.
3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
4. Batlle D, Jose Soler M, Ye M. ACE2 and diabetes: ACE of ACEs? Diabetes 2010;59:2994-6.
5. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.
6. Bilman V, Mares-Guia L, Nadu AP, Bader M, Campagnole-Santos MJ, Santos RA, et al. Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7). Peptides 2012;37:247-51.
7. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
8. Cao X, Yang FY, Xin Z, Xie RR, Yang JK. The ACE2/Ang-(1-7)/Mas axis can inhibit hepatic insulin resistance. Mol Cell Endocrinol 2014;393:30-8.
9. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008;198:22-8.
10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
11. Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009;29:748-53.
12. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-9.
13. Eriksson U, Danilczyk U, Penninger JM. Just the beginning: novel functions for angiotensin-converting enzymes. Curr Biol 2002;12:R745-52.
14. Feltenberger JD, Andrade JM, Paraiso A, Barros LO, Filho AB, Sinisterra RD, et al. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension 2013;62(Aug (2)):324-30.
15. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 2006;47:515-21.
16. Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci 2004;61:2720-7.
17. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 2000;32:1403-8.
18. Fu Z, Zhao L, Aylor KW, Carey RM, Barrett EJ, Liu Z. Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor. Hypertension 2014;63:1219-27.
19. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-24.
20. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
21. Guimaraes GG, Santos SH, Oliveira ML, Pimenta-Velloso EP, Motta DF, Martins AS, et al. Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. Peptides 2012;38:54-61.
22. Guo J, Friedman SL. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrog Tissue Repair 2010;3:21.
23. Halici Z, Bilen H, Albayrak F, Uyanik A, Cetinkaya R, Suleyman H, et al. Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes? Eur J Pharmacol 2009;614:146-52.
24. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7.
25. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007;47:387-95.
26. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
27. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007;45:1375-81.
28. Huang ML, Li X, Meng Y, Xiao B, Ma Q, Ying SS, et al. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. Clin Exp Pharmacol Physiol 2010;37:e1-6.
29. Huang Q, Xie Q, Shi CC, Xiang XG, Lin LY, Gong BD, et al. Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis. Int J Mol Med 2009;23:717-23.
30. Huang Y, Feng H, Kan T, et al. Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells. PLoS One 2013;8(8):e73492.
31. Kamide K. Role of renin-angiotensin-aldosterone system in metabolic syndrome and obesity-related hypertension. Curr Hypertens Rev 2014 (Epub 2014 Aug 12).
32. Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun 2003;308:177-83.
33. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res 2007;73:463-9.
34. Kuba K, Imai Y, Ohto-Nakanishi T, et al. Trilogy of ACE2: a peptidase in the reninangiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther 2010;128(1):119-28.
35. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004;22(12):2253-61.
36. Lee MH, Song HK, Ko GJ, Kang YS, Han SY, Han KH, et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008;74:890-900.
37. Li S, Wang L, Yan X, Wang Q, Tao Y, Li J, et al. Salvianolic acid B attenuates rat hepatic fibrosis via downregulating angiotensin II signaling. Evid Based Complement Alternat Med 2012;2012:160726.
38. Liu J, Gong H, Zhang ZT, Wang Y. Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J (Engl) 2008;121:161-5.
39. Lubel JS, Herath CB, Tchongue J, Grace J, Jia Z, Spencer K, et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 2009;117:375-86.
40. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008;134:1641-54.
41. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-74.
42. Mende S, Schulte S, Strack I, Hunt H, Odenthal M, Pryymachuck G, et al. Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4(-/-) mouse model. Dig Dis Sci 2013;58:1271-81.
43. Naik P, Murumkar P, Giridhar R, Yadav MR. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists - a perspective. Bioorg Med Chem 2010;18:8418-56.
44. Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Aihara Y, Shirai Y, et al. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. Hepatol Res 2013;43:765-74.
45. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37:1043-55.
46. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile ductligated rat liver. Gastroenterology 2002;123:1667-76.
47. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001;35:376-85.
48. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005;54:1790-6.
49. Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis 2012;16:397-419.
50. Pereira RM, dos Santos RA, da Costa Dias FL, Teixeira MM, Simoes e Silva AC. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol 2009;15:2579-86.
51. Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, et al. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol 2007;46:674-81.
52. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004;110:1507-12.
53. Qiang G, Zhang L, Yang X, Xuan Q, Shi L, Zhang H, et al. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol 2012;685:156-64.
54. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007;50:112-9.
55. Reese LJ, Tider DS, Stivala AC, Fishbein DA. Effects of angiotensin converting enzyme inhibitors on liver fibrosis in HIV and hepatitis C coinfection. AIDS Res Treat 2012;2012:978790.
56. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003;17:1803-9.
57. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008;93:519-27.
58. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258-63.
59. Santos RA, Campagnole-Santos MJ, Baracho NC, Fontes MA, Silva LC, Neves LA, et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 1994;35:293-8.
60. Santos SA, Kontorinis N, Dieterich DT. Management of chronic hepatitis C virus in patients with HIV. Curr Treat Options Gastroenterol 2005;8:433-41.
61. Santos SH, Andrade JM, Fernandes LR, Sinisterra RD, Sousa FB, Feltenberger JD, et al. Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-kappaB in rats fed with high-fat diet. Peptides 2013;46:47-52.
62. Santos SH, Braga JF, Mario EG, Porto LC, Rodrigues-Machado Mda G, Murari A, et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 2010;30:953-61.
63. Santos SH, Simoes e Silva AC. The therapeutic role of Renin-Angiotensin System blockers in obesity-related renal disorders. Curr Clin Pharmacol 2014;9:2-9.
64. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez-Leite JI, et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008;57:340-7.
65. Santos SH, Fernandes LR, Pereira CS, Guimaraes AL, de Paula AM, Campagnole-Santos MJ, et al. Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Regul Pept 2012;178:64-70.
66. Santos SH, Andrade JM. Angiotensin 1-7: a peptide for preventing and treating metabolic syndrome. Peptides 2014;59C:34-41.
67. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-32.
68. Seki E, Park E, Fujimoto J. Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis. Hepatol Res 2011;41:597-610 (the official journal of the Japan Society of Hepatology).
69. Silva AR, Aguilar EC, Alvarez-Leite JI, da Silva RF, Arantes RM, Bader M, et al. Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. Am J Physiol Regul Integr Comp Physiol 2013;305:R1323-30.
70. Simoes e Silva AC, Pinheiro SV, Pereira RM, Ferreira AJ, Santos RA. The therapeutic potential of angiotensin-(1-7) as a novel renin-angiotensin system mediator. Mini Rev Med Chem 2006;6:603-9.
71. Sipal S, Halici Z, Kiki I, Polat B, Albayrak A, Albayrak F, et al. Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy. J Mol Histol 2012;43:723-35.
72. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 2010;4:659-72.
73. Soriano V, Martin-Carbonero L, Maida I, Garcia-Samaniego J, Nunez M. New paradigms in the management of HIV and hepatitis C virus coinfection. Curr Opin Infect Dis 2005;18:550-60.
74. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003;42:574-9.
75. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005;289:H1560-6.
76. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002;36:1022.
77. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008;22:1979-91.
78. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004;141:946-56.
79. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006;364:33-60 (international journal of clinical chemistry).
80. Turkay C, Yonem O, Arici S, Koyuncu A, Kanbay M. Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis. Dig Dis Sci 2008;53:789-93.
81. Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 2006;41:996-1004.
82. Ueki M, Koda M, Shimizu T, Mitsuta A, Yamamoto T, Murawaki Y. Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepatogastroenterology 2009;56:1100-4.
83. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-43.
84. Villela DC, Passos-Silva DG, Santos RA. Alamandine: a new member of the angiotensin family. Curr Opin Nephrol Hypertens 2014;23(2):130-4.
85. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci (Lond) 2007;113:109-18.
86. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-41.
87. Wei HS, Li DG, Lu HM, Zhan YT, Wang ZR, Huang X, et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). World J Gastroenterol 2000;6:540-5.
88. Yi ET, Liu RX, Wen Y, Yin CH. Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats. Acta Pharmacol Sin 2012;33:1518-24.
89. Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006;12:322-6.
90. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5.
91. Yoshiji H, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes 2009;2:70.
92. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-50.
93. Zhang W, Miao J, Li P, Wang Y, Zhang Y. Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL(4). Res Vet Sci 2013;95:54-8.
94. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
95. Yang L, Bataller R, Dulyx J, Coffman TM, Gines P, Rippe RA, et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005;43:317-23.